The merger is supported by concurrent private financings totaling $19 million, which includes a $1 million investment from RCM Eos PIPE HOLDINGS LLC. The funds will primarily support the advancement of Eos's lead clinical candidate, PTC-2105, which targets sarcopenia and other age-related conditions. The merger has been unanimously approved by the boards of both companies and is expected to close in mid-2026, pending customary closing conditions, including stockholder approvals and the effectiveness of a registration statement with the SEC.
Upon completion of the merger, pre-merger Eos stockholders are projected to own approximately 94% of the combined company, while Pulmatrix stockholders will hold about 6%. This ownership structure reflects the significant investment and strategic value that Eos brings to the table, particularly with its innovative MitoXcel™ platform, which has shown promise in improving body composition and physical function in preclinical studies.
The merger is seen as a pivotal step for Pulmatrix, allowing it to leverage Eos's expertise in gerotherapeutics and expand its product pipeline beyond its current focus on inhaled therapeutic products. The leadership of the combined company will be headed by Dr. Kevin Slawin, Eos's founder and CEO, who brings extensive experience in biotechnology and drug development.
Overall, this merger positions the new entity to capitalize on the growing demand for therapies targeting the biological mechanisms of aging, potentially transforming the landscape of age-related disease treatment.
